The BNT162b2 mRNA Vaccine Elicits Robust Humoral and Cellular Immune Responses in People Living with Human Immunodeficiency Virus (HIV)

Bezawit A. Woldemeskel, Andrew H. Karaba, Caroline C. Garliss, Evan J. Beck, Kristy H. Wang, Oliver Laeyendecker, Andrea L. Cox, Joel N. Blankson

Research output: Contribution to journalArticlepeer-review

Abstract

Previous studies have shown that certain vaccines induce suboptimal responses in people living with human immunodeficiency virus (HIV, PLWH). However, responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines have not been fully characterized in these patients. Here we show that the BNT162b2 vaccine induces robust immune responses comparable to responses in healthy donors.

Original languageEnglish (US)
Pages (from-to)1268-1270
Number of pages3
JournalClinical Infectious Diseases
Volume74
Issue number7
DOIs
StatePublished - Apr 1 2022

Keywords

  • COVID
  • PLWH
  • SARS-CoV-2
  • mRNA vaccine

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Fingerprint

Dive into the research topics of 'The BNT162b2 mRNA Vaccine Elicits Robust Humoral and Cellular Immune Responses in People Living with Human Immunodeficiency Virus (HIV)'. Together they form a unique fingerprint.

Cite this